Molecular Biology Program

The Andrew Koff Lab



Pictured: Dr. Andrew Koff
Andrew Koff, PhD


My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major focus of the laboratory is directed towards understanding how these gene products are regulated to accomplish these roles.

View Lab Overview

Research Projects

Andrew Koff Lab Group


Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, and Koff A. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 10: 8226-43, 2015

Abbas Manji G, Singer S, Koff A, and Schwartz GK. Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book. 2015:213-8

Dickson MA, Schwartz GK, Keohan ML, D’Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, and Tap WD. Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, and Koff A. ATRX is a novel regulator of therapy induced senescence in human cells. Nat. Comms, 8:386, 2017

Kovatcheva M, Klein ME, Tap WD, and Koff A. Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol 5:e1384882, 2018

View All Publications


Pictured: Dr. Andrew Koff

Andrew Koff, PhD


  • Molecular biologist Andrew Koff is interested in identifying the genes and and molecular mechanisms by which cells make decisions regarding their proliferative capacity after they exit from the cell cycle during therapy induced senescence and during normal development.
  • PhD, State University NY at Stony Brook
Office Phone


Lab Affiliations

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrew Koff discloses the following relationships and financial interests:

  • Atropos Therapeutics, Inc.
    Ownership / Equity Interests; Provision of Services
  • Concarlo Holdings, LLC
    Provision of Services
  • Eli Lilly and Company
    Provision of Services (uncompensated)
  • PTT Global Chemical PLC and GC Ventures
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at

View all disclosures